Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients.

ABSTRACT:

Objectives

Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by cytochrome P-450 3A4/5 isoenzymes (encoded by CYP3A4 and CYP3A5). Guidelines for adjusting tacrolimus based on CYP3A5 test results are published; however, CYP3A4 variants also contribute to the variability in tacrolimus pharmacokinetics. The effects of composite phenotypes incorporating CYP3A5 and CYP3A4 increased (*1G, *1B) and decreased (*22) function variants have not been evaluated. The objective of this study is to investigate the impact of both increased and decreased function CYP3A variants on weight and dose-adjusted tacrolimus concentration (C0/D).

Methods

We performed a single-center retrospective cohort study of lung transplant recipients to evaluate the median tacrol

SUBMITTER: Liu M 

PROVIDER: S-EPMC9177686 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature